BioPharmSignal logoBioPharmSignal

Biotech News

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Adaptive Biotechnologies (ADPT)Adaptive BiotechnologiesConference / presentation

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating

Related news

IARTIntegra LifeSciences2026-09-04 13:15 EST

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

XAIRBeyond Air2026-09-02 12:00 EST

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference

SGHTSight Sciences2026-09-01 20:05 EST

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

RXSTRxSight2026-08-26 20:15 EST

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

ACHCAcadia Healthcare2026-09-09 13:00 EST

Acadia Healthcare to Participate in 2026 Jefferies Healthcare Services and Technology Conference

IRTCiRhythm2026-08-26 20:05 EST

iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference

ATRCAtriCure2026-08-25 12:00 EST

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

LMATLeMaitre Vascular2026-08-06 21:15 EST

LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

XTNTXtant Medical2026-08-04 20:05 EST

Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference

DCTHDelcath Systems2026-07-28 20:01 EST

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

View all latest news

Adaptive Biotechnologies

Adaptive Immune-System Platform Adaptive Biotechnologies develops clinical products by decoding the genetics of the adaptive immune system. Its proprietary platform measures immune-receptor sequences at scale to support disease monitoring, drug development and the discovery of immune-based therapeutics. Minimal Residual Disease The...

Recent company news

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

ADPTAdaptive Biotechnologies2026-09-01 20:05 EST

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

ADPTAdaptive Biotechnologies2026-07-09 20:05 EST

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

ADPTAdaptive Biotechnologies2026-06-30 12:30 EST

Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

Stock data

Close
28.55 USD
Market cap
2.42B USD
Exchange
NASDAQ
Sector
MedTech
Location
United States